Acadia: Acadia Stock Up 59% in a Year - Is a $51 Million New Stake a Bet on a Bigger Rebound?
Key PointsConnecticut-based fund Braidwell bought 2,378,655 shares of Acadia Pharmaceuticals in the third quarter, representing a new position valued at about $50.8 million as of September 30.
Read full article »
Acadia is a California-based biopharmaceutical company that discovers and develops novel therapies for the treatment of Parkinson’s disease.
Read more